0001104659-24-004543.txt : 20240117
0001104659-24-004543.hdr.sgml : 20240117
20240117171846
ACCESSION NUMBER: 0001104659-24-004543
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240113
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carvajal Alejandra
CENTRAL INDEX KEY: 0001645755
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 24539343
MAIL ADDRESS:
STREET 1: C/O CERULEAN PHARMA INC.
STREET 2: 840 MEMORIAL DRIVE, 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
4
1
tm243529-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-13
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001645755
Carvajal Alejandra
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
SVP, Chief Legal Officer
1
Common Stock
2024-01-13
4
M
0
8958
0
A
29284
D
Common Stock
2024-01-14
4
M
0
2500
0
A
31784
D
Common Stock
2024-01-16
4
S
0
4381
2.71
D
27403
D
Restricted Stock Unit
2024-01-13
4
M
0
8958
0
D
Common Stock
8958
26875
D
Restricted Stock Unit
2024-01-14
4
M
0
2500
0
D
Common Stock
2500
5000
D
Stock Option (Right to Buy)
3.02
2024-01-15
4
A
0
225000
0
A
2034-01-14
Common Stock
225000
225000
D
Restricted Stock Unit
2024-01-15
4
A
0
50000
0
A
Common Stock
50000
50000
D
Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 14, 2022.
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years.
The option shall vest in equal quarterly installments over four years from the date of grant.
The RSUs shall vest in equal annual installments over four years from the date of grant.
/s/ Alejandra Carvajal
2023-01-17